Latest Janet Woodcock Stories
Over a dozen regulators from Europe and USA scheduled to participate Dec. 2-4 BETHESDA, Md., Nov.
For Accelerated Approval of Therapies for Duchenne Muscular Dystrophy WASHINGTON, July 30, 2014 /PRNewswire/ -- In response to the 106,782 signatures collected through
BETHESDA, Md., June 18, 2014 /PRNewswire-USNewswire/ -- The Parenteral Drug Association has confirmed the participation of 27 officials from the U.S.
Janet Woodcock will discuss reorganization to consolidate quality-related functions. Horsham, PA (PRWEB) March 11, 2014 The U.S.
ISPE studies on Drug Shortages and Quality by Design were cited by Janet Woodcock, M.D., Director of the US FDA’s Center for Drug Evaluation and Research (CDER), in her statement associated
The FDA has suggested tighter controls on how doctors prescribe common, widely-use narcotic painkillers containing the narcotic hydrocodone.
SILVER SPRING, Md., Nov. 25 /PRNewswire-USNewswire/ -- An article by Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research, titled "A Difficult Balance - Pain Management, Drug Safety, and the FDA," appears in the Nov.
The U.S. Food and Drug Administration announced Wednesday it will require a boxed warning for the smoking cessation drugs Chantix and Zyban. The FDA said the boxed warning -- the strongest warning the agency can require -- will appear on the package insert.